Articles related to LYMPHOMA

A recent phase 3 trial comparing nivolumab plus AVD to brentuximab vedotin plus AVD in advanced-stage Hodgkin’s lymphoma demonstrated a significant improvement in 2-year progression-free survival (92% vs. 83%, respectively) with a hazard ratio for disease progression or death of 0.45 (95% CI, 0.30 to 0.65).

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

A Swedish case-control study identified a 21% increased risk of malignant lymphoma in individuals with tattoos compared to controls, prompting the need for further research into tattoo ink composition and potential long-term health effects.

Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.

The occurrence of second tumors, such as T-cell lymphomas, post-CAR T-cell therapy is rare. The study identifies Epstein-Barr virus and mutant clonal hematopoiesis as potential factors but finds no evidence of oncogenic retroviral integration, providing valuable insights for clinical practice.

A 73-year-old woman’s worsening rash and complex medical history culminated in a diagnosis of angioimmunoblastic T-cell lymphoma, underscoring the need for thorough diagnostic evaluation and aggressive treatment.